Team StartupCity

• PlasmaGen Biosciences raised Rs 150 crore in a fresh funding round led by ViNS Bioproducts, with participation from HNIs, family offices, and pharma industry entrepreneurs.
• The Bengaluru-based biopharma startup is valued at over Rs 1,500 crore and plans to use the funds to expand international operations, product portfolio, and manufacturing capabilities.
• Founded in 2010, PlasmaGen operates one of India’s few plasma fractionation facilities in Kolar, Karnataka, and is preparing to enter global markets with plasma-derived therapeutics.

Bengaluru-based biopharma startup PlasmaGen Biosciences  has received funding of Rs 150 crore led by ViNS Bioproducts along with contribution from high net worth individuals, family offices, and entrepreneurs from the pharma industry. The company, backed by Eight Road Ventures, is valued at over Rs 1,500 crore.

PlasmaGen has already scooped up more than Rs 600 crores of funds from Fidelity's FIL Capital Investments, Eight Roads Ventures, F-Prime Capital, among others.

These funds will help the company expand their international operations, enlarge their product offerings, and improve their manufacturing and leadership skills, according to a press release by PlasmaGen Biosciences.

PlasmaGen Biosciences was founded in 2010 and concentrates on developing and commercializing plasma-derived therapeutic products such as Immunoglobulin, Albumin, and coagulation factors to fill the gap of demand and supply of such a critical class of drugs in India and is working towards achieving independence in plasma products with a state-of-the-art fractionation facility setup in Kolar, Karnataka.

Also Read: Furlenco Bags Rs 125 Crore to Expand Portfolio, Scale Omnichannel Growth

According to PlasmaGen, the company has come up with distribution partners in the principal exporting regions and is in the process of obtaining the necessary approvals for the distribution and sale of the drug in these regions. The Indian market continues to be one of the most important for the company.

PlasmaGen claims that it has started operations in 2024 at its plasma fractionation facility located in Kolar, close to Bengaluru. According to the firm, the infrastructure is one of only five plasma fractionation facilities in the country and is the first pure-play plasma biopharma company and is now ready to enter the international market.